SCHEMBL5176124

SCHEMBL5176124

CCC(C)(C)c1ccc(C(=O)NCCc2ccc(Cl)c(Cl)c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.62
ESRRG P62508 7/20 0.55
ESRRB O95718 2/20 0.52
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
GAA P10253 2/20 0.50
LIPG Q9Y5X9 1/20 0.48
HPGD P15428 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C19 P33261 1/20 0.48
GFER P55789 1/20 0.48
HTT P42858 2/20 0.48
POLB P06746 1/20 0.48
PTGDR2 Q9Y5Y4 1/20 0.48
CNR1 P21554 1/20 0.47
ALDH1A1 P00352 1/20 0.47
FABP2 P12104 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3940148 0.83 TRPV1 (0.65) TRPV1ESRRGNPC1RAB9AGAA
SCHEMBL1386961 0.81 TRPV1 (0.70) TRPV1ESRRGESRRBNPC1RAB9A
SCHEMBL5175816 0.80 TRPV1 (0.69) TRPV1ESRRGESRRBNPC1RAB9A
SCHEMBL3573110 0.80 TRPV1 (0.64) TRPV1ESRRGNPC1RAB9AGAA
SCHEMBL5176430 0.80 TRPV1 (0.68) TRPV1ESRRGESRRBNPC1RAB9A
SCHEMBL3391330 0.80 TRPV1 (0.65) TRPV1ESRRGNPC1RAB9AGAA
SCHEMBL5177620 0.79 CYP1A2 (0.52) CYP1A2CYP2D6CYP2C19CA1CA2
SCHEMBL5177863 0.78 ESRRG (0.70) TRPV1ESRRGESRRBNPC1RAB9A
SCHEMBL1397547 0.76 ESRRG (0.52) TRPV1ESRRGESRRBNPC1RAB9A
SCHEMBL3018128 0.74 HDAC6 (0.61) TRPV1ESRRGNPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7259183-B2 Indole, indazole and indoline derivatives as CETP inhibitors HOFFMANN-LA ROCHE INC. (US) 2007-08-21 US disclosed
EP-1776338-A1 INDOLE, INDAZOLE OR INDOLINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2007-04-25 EP disclosed
US-20060030613-A1 Indole, indazole and indoline derivatives as CETP inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2006-02-09 US disclosed
WO-2006013048-A1 INDOLE, INDAZOLE OR INDOLINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030613-A1 Indole, indazole and indoline derivatives as CETP inhibitors CETP, NAT1, MTTP TRPV1 1818/4885ESRRG 3392/4885ESRRB 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.